peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

GLP-1 receptor agonist

Albiglutide

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

In contracting human atrial tissue, albiglutide (100 nM) plus cilostamide (100 nM) increased phosphorylation of phospholamban and troponin’s inhibitory subunit. In isolated adult mouse atrial tissue, albiglutide (100 nM) did not increase contraction force or beating rate, whether rolipram (100 nM) was present or not.

Sources for this introduction: [1] [2]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

How does it work?

Target, response, and disposition.

Mechanism

In contracting human atrial tissue, albiglutide (100 nM) plus cilostamide (100 nM) increased phosphorylation of phospholamban and troponin’s inhibitory subunit.

Sources[1]pubmedContractile effects of albiglutide in the human and mouse atrium.In contracting HAP, 100 nM albiglutide in the presence of 100 nM cilostamide increased the phosphorylation state of phospholamban and the inhibitory subunit of troponin.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “In contracting HAP, 100 nM albiglutide in the presence of 100 nM cilostamide increased the phosphorylation state of phospholamban and the inhibitory subunit of troponin.”

    Contractile effects of albiglutide in the human and mouse atrium. · Abstract

    pubmed:42490806:4ade9f4d91a1:4ade9f4d91a1

What has been studied?

What the evidence says.

Study findings

In isolated atrial preparations from adult mice, 100 nM albiglutide showed no positive inotropic or chronotropic increase under baseline conditions or during PDE4 inhibition (rolipram 100 nM).

Sources[1]pubmedContractile effects of albiglutide in the human and mouse atrium.In contrast, 100 nM albiglutide did not increase the force of contraction or the beating rate in isolated left atrial or right atrial preparations from adult mice in the presence and absence of the phosphodiesterase 4 inhibitor rolipram (100 nM).
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “In contrast, 100 nM albiglutide did not increase the force of contraction or the beating rate in isolated left atrial or right atrial preparations from adult mice in the presence and absence of the phosphodiesterase 4 inhibitor rolipram (100 nM).”

    Contractile effects of albiglutide in the human and mouse atrium. · Abstract

    pubmed:42490806:4ade9f4d91a1:4ade9f4d91a1

Study findings

In isolated adult mouse atrial tissue, albiglutide (100 nM) did not increase contraction force or beating rate, whether rolipram (100 nM) was present or not.

Sources[1]pubmedContractile effects of albiglutide in the human and mouse atrium.In contrast, 100 nM albiglutide did not increase the force of contraction or the beating rate in isolated left atrial or right atrial preparations from adult mice in the presence and absence of the phosphodiesterase 4 inhibitor rolipram (100 nM).
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “In contrast, 100 nM albiglutide did not increase the force of contraction or the beating rate in isolated left atrial or right atrial preparations from adult mice in the presence and absence of the phosphodiesterase 4 inhibitor rolipram (100 nM).”

    Contractile effects of albiglutide in the human and mouse atrium. · Abstract

    pubmed:42490806:4ade9f4d91a1:4ade9f4d91a1

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, identity, interaction, regulatory, safety
  • 116 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (70), assurance_score_below_0.72 (45), current_regulatory_source_required (28), extraction_ambiguity (55), extraction_confidence_not_high (1), high_risk_requires_regulatory_or_two_independent_sources (45), no_direct_support (113), proposal_not_staged (2)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Contractile effects of albiglutide in the human and mouse atrium. ↗

    pubmed · published 2026-01-01 · retrieved 2026-08-25T22:30:24Z

Publication history and provenance

Version 6 · Automated assessment · 2026-08-25T22:30:24Z

6a44eb72e954cb736450e086fdf2360ac798d747e3d45803d30eb07fc5e30945